EVEROLIMUS (AFINITOR): NOVYE VOZMOZhNOSTI TERAPII ZLOKAChESTVENNYKh OPUKhOLEY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of a clinical evaluation of the effects of the mTOR inhibitor everolimus (Afinitor) in various malignancies. The drug binds an intracellular protein, leading to inhibition of mTOR-kinase activity. Additionally, it inhibits the expression of hypoxia-inducing factor and reduces the expression of epidermal growth factor (EGFR). Originally, everolimus was approved by the U.S. FDA as a drug for 2nd line treatment of advanced renal cell carcinoma. Then, he was approved for the treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis, progressive neuroendocrine tumors of the pancreas, and renal angiolipomyoma as a the complex lesions in tuberous sclerosis. HR +-, HER2- metastatic breast cancer previously treated with nonsteroidal aromatase inhibitors became the latest indication for the application of everolimus (2012). The potentials for the expanding clinical use of everolimus are discussed.

Full Text

Restricted Access

About the authors

V. A Gorbunova

References

  1. Yao J.A., Lombard-Bohas C., Baudin E., et al. Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial. J. Clin. Oncol. 2010; 28(1): 69-76.
  2. Pavel M.E., Hainsworth J.D., Baudin E., et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011; 378(9808): 2005-12.
  3. Miller T.W., Rexer B.N., Garrett J.T., et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011; 13(6): 224.
  4. Johnston S.R. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin. Breast Cancer. 2009; 9(Suppl 1): S28-36.
  5. Baselga J., et al. J. Clin. Oncol. 2008; 27(16): 2630-37.
  6. Reprinted from Campone M, et al. ESMO. 2012. Abstract 324PD.
  7. Baselga J., et al. N. Engl. J. Med. 2012; 366(6): 520-29.
  8. Hortobagyi G., et al. SABCS. 2011. Abstract S3-7 (oral).
  9. Piccart M., et al. J. Clin Oncol. 2012; 30(suppl): abstr. 559 (poster).
  10. Piccart M., Hortobagyi G., et al. Everolimus Plus Exemestane for Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor-2-Negative (HER2-) Advanced Breast Cancer (BC): Overall Survival Results From BOLERO-2. Presented at EBCC-9; 19-21 March 2014; Glasgow, Scotland. Abstract 1LBA.
  11. Beck J.T., Hortobagyi G., Campone M., et al. Everolimus plus exemestane as first-line therapy in HR+, HER2-advanced breast cancer in BOLERO-2. Breast Cancer Res. Treat. 2014; 143(3): 459-67.
  12. Hortobagyi G. Greater PFS Benefit With EVE in Patients With Minimal Alterations in PIK3CA/PTEN/CCND1 or FGFR1/2. Presented at ASCO; May 31-June 4, 2013, Chicago; abstract LBA509.
  13. Johnston S.R. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res. 2005; 11(2 Pt 2): 889S-99S.
  14. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372; 449-56.
  15. Yao J.C., Shah M.H., Ito T., et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) study group. N. Engl. J. Med. 2011; 364: 514-23.
  16. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012; 366: 520-29.
  17. Bissler J.J., Kingswood C., Zonnenberg B.A., et al. Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: results from EXIST-2. J. Clin. Oncol. 2012; 30(Suppl 5): Abstract 356.
  18. Subramaniam S., Zell J.A., Kunz P.A. Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis. J. Natl. Compr. Canc. Netw. 2013; 11: 5-9.
  19. Ramirez-Fort M.K., Case E.C., Rosen A.C., et al. Rash to the mTOR Inhibitor Everolimus. Systematic Review and Meta-Analysis. Am. J. Clin. Oncol. 2012 Dec 13. Epub ahead of print.
  20. Martins F., de Oliveira M.A., Qian Wang Q., et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol. 2013; 49(4): 293-98.
  21. Sanchez-Fructuoso A.I. Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin. Drug Metab. Toxicol. 2008; 4: 807-19.
  22. Porta C., Osanto S., Ravaud A., et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer. 2011; 47: 1287-98.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media